Introduction
Subjects and methods
Research subjects
Criteria
Procedural characteristics
Endpoints and follow-up
Statistical analysis
Results
Variable | Overall (n = 109) | BMI (kg/m2) | p-value | ||
---|---|---|---|---|---|
< 21.9 (n = 27) | 21.9–27.0 (n = 55) | > 27.0 (n = 27) | |||
Age (years) | 72.0 ± 8.8 | 71.2 ± 7.4 | 72.0 ± 7.4 | 74.8 ± 8.8 | < 0.001 |
Men | 67 (61.5%) | 18 (66.7%) | 31 (56.4%) | 18 (66.7%) | 0.543 |
Body mass index (kg/m2) | 25.0 [21.9, 27.0] | 20.3 [19.4, 21.2] | 25.0 [23.4, 25.9] | 30.3 [28.0, 34.4] | < 0.001 |
New York Heart Association class III or IV | 87 (79.8%) | 21 (77.8%) | 44 (80.0%) | 22 (81.5%) | 0.943 |
Hypertension | 94 (86.2%) | 21 (77.8%) | 48 (87.3%) | 25 (92.6%) | 0.310 |
Diabetes mellitus | 37 (33.9) | 7 (25.9%) | 15 (27.3%) | 15 (55.6%) | 0.026 |
Previous myocardial infarction | 16 (14.7%) | 5 (18.5%) | 6 (10.9%) | 5 (18.5%) | 0.593 |
Previous coronary artery bypass graft | 18 (16.5%) | 4 (14.8%) | 8 (14.5%) | 6 (22.2%) | 0.708 |
Previous percutaneous coronary intervention | 28 (25.7%) | 4 (14.8%) | 12 (21.8%) | 12 (44.4%) | 0.026 |
Previous valve surgery | 5 (4.6%) | 2 (7.4%) | 2 (3.6%) | 1 (3.7%) | 0.836 |
Peripheral artery disease | 36 (33.0%) | 8 (29.6%) | 18 (32.7%) | 10 (37.0%) | 0.834 |
Previous stroke/transient ischemic attack | 18 (16.5%) | 4 (14.8%) | 8 (14.5%) | 6 (22.2%) | 0.708 |
Chronic lung diseasea | 37 (33.9%) | 4 (14.8%) | 22 (40.0%) | 11 (40.7%) | 0.051 |
Glomerular filtration rate (mL/min/m2) | 55.9 ± 25.5 | 61.4 ± 17.0 | 55.9 ± 19.6 | 50.0 ± 15.2 | 0.024 |
Previous pacemaker | 14 (12.8%) | 3 (11.1%) | 9 (16.4%) | 2 (7.4%) | 0.570 |
Atrial fibrillation | 27 (24.8%) | 4 (14.8%) | 19 (34.5%) | 4 (14.8%) | 0.064 |
Frailtyb | 31 (28.4%) | 5 (18.5%) | 13 (23.6%) | 13 (48.1%) | 0.032 |
Ejection fraction (%) | 56.8 ± 14.9 | 56.0 ± 14.9 | 58.0 ± 13.2 | 56.3 ± 10.4 | 0.250 |
Aortic valve area (cm2) | 0.63 ± 0.16 | 0.63 ± 0.15 | 0.63 ± 0.16 | 0.64 ± 0.15 | 0.998 |
Aortic valve mean gradient (mm Hg) | 45.4 ± 13.6 | 46.0 ± 13.3 | 44.9 ± 14.2 | 45.4 ± 13.0 | 0.386 |
Aortic valve maximal gradient (mm Hg) | 76.2 ± 21.4 | 77.1 ± 20.8 | 74.2 ± 22.2 | 77.0 ± 20.5 | 0.286 |
CT mean annulus diameter (mm) | 24.3 ± 2.7 | 24.3 ± 2.8 | 24.4 ± 2.5 | 24.2 ± 2.5 | 0.980 |
Variable | BMI (kg/m2) | p-value | ||
---|---|---|---|---|
< 21.9 (n = 27) | 21.9–27.0 (n = 55) | > 27.0 (n = 27) | ||
Implanted valve | 1.000 | |||
VitaFlow®a | 23 (85.2%) | 48 (87.3%) | 23 (85.2%) | |
J-Valveb | 4 (14.8%) | 7 (12.7%) | 4 (14.8%) | |
Implanted valve size (mm) | ||||
21 (VitaFlow®) | 8 (29.6%) | 16 (29.1%) | 6 (22.2%) | 0.532 |
24 (VitaFlow®) | 14 (51.9%) | 25 (45.4%) | 12 (44.5%) | |
27 (VitaFlow®) | 5 (18.5%) | 14 (25.5%) | 7 (25.9%) | |
30 (VitaFlow®) | 0 (0.0%) | 0 (0.0%) | 2 (7.4%) | |
Vascular access | ||||
Transfemoral | 22 (81.5%) | 48 (87.3%) | 24 (88.9%) | 0.762 |
Transapical | 5 (18.5%) | 7 (12.7%) | 3 (11.1%) | |
Device success | 25 (92.6%) | 54 (98.2%) | 25 (92.6%) | 0.280 |
2nd valve | 2 (7.4%) | 2 (3.6%) | 1 (3.7%) | 0.836 |
Postdilatation | 3 (11.1%) | 6 (10.9%) | 4 (14.8%) | 0.936 |
Valve embolization | 1 (3.7%) | 0 (0.0%) | 0 (0.0%) | 0.495 |
Fluoroscopy time (min) | 17.8 ± 7.1 | 15.9 ± 7.0 | 16.2 ± 8.8 | 0.638 |
Total contrast used (ml) | 85.9 ± 47.6 | 89.2 ± 42.8 | 90.1 ± 40.2 | 0.236 |
TEE postprocedural PVL | ||||
None/trace | 22 (81.5%) | 43 (78.2%) | 21 (77.8%) | 1.000 |
Mild | 5 (18.5%) | 11 (20.0%) | 5 (18.5%) | |
Moderate | 0 (0.0%) | 1 (1.8%) | 1 (3.7%) | |
Severe | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Postprocedural aortic valve gradient (mm Hg) | 8.5 ± 4.6 | 9.5 ± 5.0 | 8.5 ± 5.0 | 0.383 |
Variable | Overall (n = 109) | BMI (kg/m2) | ||
---|---|---|---|---|
< 21.9 (n = 27) | 21.9–27.0 (n = 55) | > 27.0 (n = 27) | ||
30-day Mortality | 5 (4.6%) | 1 (3.7%) | 3 (5.5%) | 1 (3.7%) |
Cerebrovascular accident/transient ischemic attack | 3 (2.8%) | 1 (3.7%) | 1 (1.8%) | 1 (3.7%) |
Myocardial infarction | 2 (1.8%) | 0 (0.0%) | 1 (1.8%) | 1 (3.7%) |
Respiratory failure | 7 (6.4%) | 2 (7.4%) | 3 (5.5%) | 2 (7.4%) |
Cardiogenic shock | 3 (2.8%) | 1 (3.7%) | 2 (3.6%) | 0 (0.0%) |
Cardiac tamponade | 1 (0.9%) | 1 (3.7%) | 0 (0.0%) | 0 (0.0%) |
Major bleeding | 2 (1.8%) | 1 (3.7%) | 1 (1.8%) | 0 (0.0%) |
Major vascular complications | 4 (3.7%) | 1 (3.7%) | 2 (3.6%) | 1 (3.7%) |
Minor vascular complications | 8 (7.3%) | 4 (14.8%) | 3 (5.5%) | 1 (3.7%) |
New permanent pacemaker implantation | 7 (6.4%) | 2 (7.4%) | 3 (5.5%) | 2 (7.4%) |
Acute kidney injury stage 3 | 13 (11.9%) | 4 (14.8%) | 7 (12.7%) | 2 (7.4%) |
New York Heart Association functional class | 1.83 ± 0.7 | 1.81 ± 0.9 | 1.83 ± 0.9 | 1.80 ± 0.7 |
Variable | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95%CI |
p
| HR | 95%CI |
p
| |
BMI (categorical) | ||||||
Middle versus Low | 1.662 | 0.365–6.985 | 0.438 | 1.124 | 0.866–1.974 | 0.500 |
High versus Low | 0.887 | 0.368–0.935 | 0.029 | 1.231 | 0.920–1.995 | 0.738 |
BMIa (kg/m2) | 0.959 | 0.922–0.968 | 0.032 | |||
Age (years) | 3.119 | 1.192–5.106 | 0.043 | 1.168 | 0.993–1.867 | 0.323 |
Male | 1.032 | 0.988–1.996 | 0.788 | 0.855 | 0.733–1.457 | 0.534 |
Diabetes mellitus | 0.932 | 0.329–2.503 | 0.779 | 3.930 | 1.995–4.885 | 0.034 |
Chronic lung disease | 1.986 | 0.392–2.831 | 0.409 | 1.306 | 0.156–1.887 | 0.460 |
CAD | 1.988 | 0.959–2.887 | 0.569 | 1.004 | 0.566–1.661 | 0.660 |
Previous MI | 0.925 | 0.780–2.944 | 0.099 | |||
Previous CABG or valve surgery | 0.317 | 0.102–0.980 | 0.328 | |||
Previous stroke/TIA | 0.878 | 0.884–1.488 | 0.587 | |||
GFR (mL/min/m2) | 0.898 | 0.877–1.219 | < 0.001 | 3.006 | 1.876–3.301 | 0.046 |
Atrial fibrillation | 1.318 | 1.259–2.916 | 0.04 | 1.558 | 0.885–2.432 | 0.120 |
Frailty | 3.125 | 2.035–3.152 | < 0.001 | 3.825 | 1.968–4.730 | 0.003 |
Ejection fraction | 0.958 | 0.881–0.976 | 0.01 | 1.678 | 0.807–1.806 | 0.063 |
Aortic valve mean gradient (mm Hg) | 1.798 | 1.195–1.989 | 0.004 | 1.806 | 1.606–1.965 | 0.122 |
Aortic valve area (cm2) | 1.006 | 0.625–1.986 | 0.763 | |||
Valve type: VitaFlow®/J-Valve | 1.160 | 0.914–1.246 | 0.108 | 1.803 | 0.875–1.954 | 0.098 |
Alternative access: Transfemoral/Transapical | 2.940 | 1.338–2.957 | < 0.001 | 1.551 | 1.022–1.997 | 0.088 |
Variable | Overall (n = 109) | BMI (kg/m2) | p-value | ||
---|---|---|---|---|---|
< 21.9 (n = 27) | 21.9–27.0 (n = 55) | > 27.0 (n = 27) | |||
Intubation time (hours) | 9.1 ± 6.9 | 8.7 ± 4.2 | 8.9 ± 6.0 | 9.1 ± 7.3 | 0.872 |
Baseline PaO2/FiO2 (mmHg) | 446.67 ± 50.95 | 451.90 ± 58.35 | 437.72 ± 78.85 | 379.88 ± 73.35 | 0.038 |
Transitional extubation, PaO2/FiO2 (mmHg) | 386.67 ± 67.88 | 426.84 ± 59.54 | 366.85 ± 69.78 | 300.65 ± 70.40 | 0.030 |
Postextubation 12th hour, PaO2/FiO2 (mmHg) | 417.58 ± 55.15 | 438.80 ± 65.98 | 410.10 ± 45.58 | 345.20 ± 50.35 | 0.043 |
Postextubation 24th hour, PaO2/FiO2 (mmHg) | 418.18 ± 64.24 | 425.02 ± 29.54 | 405.56 ± 58.85 | 420.80 ± 69.52 | 0.856 |
Postextubation 48th hour, PaO2/FiO2 (mmHg) | 426.06 ± 36.06 | 442.89 ± 60.38 | 384.05 ± 36.85 | 423.65 ± 49.97 | 0.896 |
Postextubation 72th hour, PaO2/FiO2 (mmHg) | 393.67 ± 46.06 | 407.28 ± 45.58 | 405.38 ± 35.54 | 392.59 ± 41.88 | 0.873 |
Variable | Odds ratio | 95% Confidence interval | Overall p-value |
---|---|---|---|
BMI (kg/m2) | |||
BMI: Low | 1.000 | ||
BMI: Middle | 2.226 | 0.996–11.875 | 0.157 |
BMI: High | 2.768 | 0.998–13.085 | 0.235 |
Chronic lung disease | |||
No | 1.000 | ||
Yes | 8.038 | 3.682–38.096 | 0.001a |